Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception ...

The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first ...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney fai ...

The sporting goods industry stepped onto the global health stage at a landmark side event at the World Health Assembly this week in Geneva, hosted by the World Federation of the Sporting Goods ...

On 14 December 2021, CSL announced its intention to acquire Vifor Pharma, an iron deficiency and nephrology treatment company, for US$11.7 billion. That acquisition was completed on 9 August 2022.

May 21 (Reuters) - Indian drugmaker Mankind Pharma (MNKI.NS), opens new tab reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its ...

(Reuters) -Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its drugs to treat long-term illnesses. The ...

For each €0.10 of cash received one private non-tradable warrant to purchase one share, subject to the adjustment below, will be issued with an exercise price of €0.10. Maturity of the warrants is 24 ...

Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling Participants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov ...

For each €0.10 of cash received one private non-tradable warrant to purchase one share, subject to the adjustment below, will be issued with an exercise price of €0.10. Maturity of the ...